Key Points
- United Therapeutics EVP Paul Mahon sold 8,300 shares at an average price of $544.30, generating approximately $4.52 million and reducing his direct stake by 15.52% to 45,172 shares.
- UTHR shares traded at $533.12 following the disclosure, with the stock holding a market capitalization of about $22.87 billion and trading below its one-year high of $609.35.
- Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $642.69, despite recent revenue declining 1.9% year over year.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the company's stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $544.30, for a total value of $4,517,690.00. Following the transaction, the executive vice president directly owned 45,172 shares in the company, valued at $24,587,119.60. This represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
United Therapeutics Price Performance
United Therapeutics stock traded down $8.39 during mid-day trading on Friday, reaching $533.12. The company had a trading volume of 654,280 shares, compared to its average volume of 992,596. United Therapeutics Corporation has a 1 year low of $409.07 and a 1 year high of $609.35. The company has a market capitalization of $22.87 billion, a P/E ratio of 19.07, a P/E/G ratio of 3.87 and a beta of 0.49. The stock's 50-day simple moving average is $513.64 and its 200-day simple moving average is $540.40.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million for the quarter, compared to analysts' expectations of $804.65 million. During the same period in the prior year, the company earned $6.41 EPS. The firm's revenue was down 1.9% on a year-over-year basis. On average, equities analysts forecast that United Therapeutics Corporation will post 26.40 EPS for the current fiscal year.
Key Stories Impacting United Therapeutics
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: United Therapeutics settled six patent and antitrust disputes with Liquidia, reducing legal uncertainty around Liquidia’s YUTREPIA inhaled treprostinil treatment. The agreement limits YUTREPIA’s label, including excluding pulmonary hypertension associated with interstitial lung disease, which could help protect UTHR’s competitive position. United Therapeutics Settles Litigation And Resets Pulmonary Hypertension Competition
- Positive Sentiment: The settlement is expected to provide United Therapeutics with approximately $380.7 million in payments, while giving investors greater visibility into the competitive landscape for treprostinil therapies. United Therapeutics Stock May Be Undervalued Following the Litigation Settlement
- Positive Sentiment: Traders purchased 12,089 UTHR call options, roughly 220% above average daily volume. The activity signals increased bullish speculation, although options flow does not guarantee sustained buying in the shares.
- Positive Sentiment: Analyst sentiment remains generally favorable. Jefferies reaffirmed a Buy rating with a $728 target, and the broader analyst consensus remains “Moderate Buy,” with targets above recent trading levels.
- Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $5.13 million, reducing her holdings by 2.84%. She still retains a substantial position, so the sale may reflect personal financial planning rather than a change in the company’s outlook. United Therapeutics CEO Stock Sale SEC Filing
- Negative Sentiment: EVP Paul Mahon sold 8,300 shares for approximately $4.52 million, cutting his direct stake by 15.52%. The second executive sale disclosed within two days may weigh on sentiment, even though insider transactions alone do not establish a deterioration in fundamentals. United Therapeutics EVP Stock Sale SEC Filing
Wall Street Analyst Weigh In
UTHR has been the subject of several recent research reports. Royal Bank Of Canada increased their price target on United Therapeutics from $677.00 to $708.00 and gave the company an "outperform" rating in a report on Thursday, October 8th. Morgan Stanley lifted their price target on shares of United Therapeutics from $515.00 to $566.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 7th. Cantor Fitzgerald reiterated an "overweight" rating on shares of United Therapeutics in a report on Thursday, October 1st. Jefferies Financial Group reissued a "buy" rating and issued a $728.00 price objective on shares of United Therapeutics in a research report on Wednesday. Finally, JPMorgan Chase & Co. upped their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a research report on Thursday, July 23rd. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $642.69.
View Our Latest Research Report on UTHR
Hedge Funds Weigh In On United Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Arjuna Capital lifted its position in shares of United Therapeutics by 2.8% during the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company's stock valued at $393,000 after purchasing an additional 18 shares in the last quarter. Sage Rhino Capital LLC grew its position in United Therapeutics by 5.1% in the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company's stock worth $281,000 after purchasing an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC grew its position in United Therapeutics by 5.4% in the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company's stock worth $276,000 after purchasing an additional 24 shares in the last quarter. Meeder Advisory Services Inc. increased its stake in United Therapeutics by 4.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company's stock valued at $392,000 after buying an additional 26 shares during the last quarter. Finally, Kera Capital Partners Inc. increased its stake in United Therapeutics by 6.1% in the 1st quarter. Kera Capital Partners Inc. now owns 471 shares of the biotechnology company's stock valued at $279,000 after buying an additional 27 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company's products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.
United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
